**Introduction**

Estrogens are naturally occurring hormones from androgen precursors in the ovarian follicles of premenopausal women under the influence of the pituitary. They are given for replacement therapy in deficiency states for menopausal, postmenopausal disorders and contraception. They are administered orally, subcutaneously via an implant, locally as vaginal cream or tablets, intramuscularly or transdermally via a skin patch. Also, they are also used in the management of breast cancer in menopausal and postmenopausal women and in the management of prostate cancer [1].

Estriol, (1,3,5,(10)-estratriene-3,16α, 17β-triol), is by far the most abundant estrogen present in pregnant mammals. Oral estriol tablets have been used with good results, primarily for the treatment of local urogenital complaints in postmenopausal women for over 40 years. One of its product characteristics is that it does not stimulate the endometrium. Therefore, it can be used uninterrupted without the cyclical addition of a progestogen to protect the endometrium. Although all available data confirm the endometrial safety of oral estriol tablets, it is considered relevant to update the existing long-term data on this topic [2,3].

Several methods have been reported for determination of estriol including HPLC [4], immunooassay [5] and GC-MS [6] in biological samples. Since most chromatographic methods have been developed for environmental samples, immunooassay is the preferred techniques for biological samples because of its specificity and sensitivity. Radioimmunoassay (RIA) [7], enzyme immunoassay (EIA) [8] and fluorescence immunooassay (FIA) [9] have been widely applied in screening and determination of estriol. RIA allows rapid and sensitive screening of large number of samples. However, the major disadvantage of this conventional technique is that it requires radioisotopes and produces radioactive waste. Although EIA and FIA are inexpensive, they are labor-intensive and not sensitive enough for determination of estriol.

To our knowledge, there is no GC-MS method for determination of estriol in pharmaceutical preparations in literature. Therefore, we report GC-MS and HPLC methods for determination of estriol in pharmaceutical preparations. The proposed methods in this study are accurate, sensitive, and precise and can be easily applied to Gynoflor tablet as pharmaceutical preparation. The results obtained by the methods were statistically compared and there was no significant difference between two methods.

**Materials and Methods**

**Chemicals**

Estriol was obtained from Hıfzıssıhha Laboratory (Erzurum, Turkey). Acetonitrile (HPLC grade) was purchased from Fluka (Buchs, Switzerland), and other chemicals and solvents used were of analytical grade. N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Gynoflor tablet containing 0.03 mg of estriol was obtained from pharmacy (Erzurum, Turkey).

**GC-MS conditions**

Chromatographic analysis was carried out on an Agilent 6890N gas chromatography system equipped with 5973 series mass selective detector, 7673 series auto sampler and chromatst (Agilent Technologies, Palo Alto, CA). HP-5 MS column with 0.25μm film thickness (30m x 0.25mm I.D., USA) was used for separation. Split less injection was used and the carrier gas was helium at a flow rate of 2 ml/min. The MS detector parameters were transfer line temperature 280°C, solvent delay 3 min and electron energy 70 eV.

**HPLC conditions**

A Perkin Elmer series 200 HPLC system equipped with programmable fluorescence detector and Total Chromatography Data System software was used (Perkin Elmer Life and Science,
Shelton, CT, USA). Separation was achieved using an Ace C18 column (5µm, 4.6x250mm i.d.) with a guard column (4mm × 3mm i.d., Phenomenex) packed with the same material at a flow rate of 1 ml/min. The injection volume was 20µl. The eluent was monitored by fluorescence detection at 280nm (excitation) and 310nm (emission).

**Preparation of stock and standard solutions**

The stock solution of estriol was prepared with acetonitrile to a concentration of 1000 ng/ml and stored at -20°C under refrigeration. Standard solutions were prepared as 12.5-500ng/ml for GC-MS and 10-400ng/ml for HPLC. The quality control (QC) solutions were prepared by adding aliquots of standard working solution of estriol to final concentrations of 75, 250 and 450ng/ml for GC-MS and 75, 250 and 350ng/ml for HPLC.

**Procedure for pharmaceutical preparation**

The average tablet mass was calculated from the mass of tablets of Gynoflor (0.03 mg estriol tablet, which was composed of estriol and some excipients). They were then finely ground, homogenized and portion of the powder was weighed accurately, transferred into a 10 ml brown measuring flask and diluted to scale with acetonitrile. The mixture was sonicated for at least 10 min to aid dissolution and then filtered through a Whatman 42 paper. An appropriate volume of filtrate was diluted further with acetonitrile so that the concentration of estriol in the final solution was within the working range and then analyzed by GC-MS and HPLC.

**Data analysis**

All statistical calculations were performed with the Statistical Product and Service Solutions (SPSS) for Windows, version 10.0. Correlations were considered statistically significant if calculated P values were 0.05 or less.

**Results and Discussion**

**Method development and optimization**

The method development for the assay of estriol was based on its chemical properties. The column and acquisition parameters were chosen to be a starting point for the method development. Estriol is a polar molecule. Therefore, the capillary column coated with 5% phenyl and 95% dimethylpolysiloxane is a good choice for separation of estriol. GC-MS method sensitivity is not enough for the determination of estriol. For this reason, MSTFA was chosen as a chromogenic derivatization reagent.

*MSTFA* is an effective trimethylsilyl donor. MSTFA reacts to replace labile hydrogens on a wide range of polar compounds with a -Si(CH₃)₃ group and is used to prepare volatile and thermally stable derivatives for GC-MS [10]. The hydroxy (-OH) groups, which render the compounds non-volatile and polar, were converted to the corresponding silyl (-O-TMS) groups, thereby rendering them volatile and non-polar. The effects of time and temperature on the reaction were investigated. To 50µl of 1000ng/ml estriol solution and 50µl of MSTFA solution was added and reacted at room temperature, 50°C and 75°C for 5 min, 10min and 20min. The resulting samples were quantitated by GC-MS system. After standing for 10min at room temperature, maximum peak areas were quantitated.

Different temperature programs were investigated for GC-MS method. The injection port and detector temperatures were set to 250 and 290°C, respectively. The end of this investigation, the temperature program of GC-MS was as follows: initial temperature was 140°C, held for 1.0min, and then increased to 310°C at a rate of 40°C/min for 2.5min. The injector volume was 1µl in split less mode.

During HPLC method development, it was focused on the optimization of column detection, sample preparation and chromatographic separation. Reversed-phase column (C₁₈) can be used for the separation of non-ionic as well as ion forming non-polar to medium polar substances while normal phase chromatography can be used for the separation of non-ionic and/or non-polar substances. Majority of the ionizable pharmaceutical compounds can be very well separated on C₁₈. Thus, estriol can be satisfactorily separated by reversed phase chromatography.

Several tests were performed for optimizing the components of mobile phase in order to achieve good chromatographic peak shape and resolution. The test results showed that the solvent system of water could improve the peak shapes of estriol. Good separation of target compounds and short run time were obtained using a mobile phase system of water containing 0.1% trifluoroacetic acid (TFA)-methanol (40:60, v/v). The retention time of estriol (3.60 min) was quite short than that studied by Tagawa et al. [4]. On the other hand, the mobile phase in the proposed method methanol-water instead of buffered systems is used in previously reported HPLC method [4]. Therefore, flushing of the column after analysis is not required.
Method validation

System Suitability: A system suitability test of the HPLC system was performed before each validation run. Five replicate injections of a system suitability/calibration standard and one injection of a check standard were made. Area relative standard deviation, tailing factor and efficiency for the five suitability injections were determined. The check standard was quantified against the average of the five suitability injections. For all sample analyses, the tailing factor was ≤ 1.12, efficiency ≥ 2045 and %RSD ≤ 1.83%.

Specificity: The specificity of the two methods was investigated by observing interferences between estriol and the excipients. For GC-MS, electron impact mode with selected ion monitoring (SIM) was used for quantitative analysis (m/z 504 for estriol). The mass spectrum after derivatization of estriol with MSTFA is shown in Figure 1.

The retention time of estriol-tri-TMS for GC-MS was approximately 6.82 min (Figure 2). Also, HPLC analysis was performed in less than 5 min (Figure 3).

Linearity: For GC-MS and HPLC measurements, the solutions were prepared by dilution of the stock solution of estriol to reach a concentration range of 12.5-500 ng/ml (12.5, 25, 50, 100, 250, 400 and 500 ng/ml) and 10-400 ng/ml (10, 25, 50, 100, 200, 300 and 400 ng/ml), respectively. Calibration curves were constructed for estriol standard by plotting the concentration of compound versus peak area response. The calibration curves were evaluated by its correlation coefficients. The correlation coefficients (r) of all the calibration curves were consistently greater than 0.99. The linear regression equations were calculated by the least squares method using Microsoft Excel® program and summarized in Table 1.

Precision and accuracy: Assay precision was determined by repeatability (intra-day) and intermediate precision (inter-day). Repeatability during the same day and intermediate precision on different days (3 days) were evaluated with six replicates of QC samples. The accuracy of this analytic method was assessed as the percentage relative error. The intra-day RSD was ≤ 4.72% and the inter-day RSD was ≤ 6.25% for QC samples. The intra- and inter-day relative error for accuracy was ≤ 3.52%. Results are shown in Table 2.

Limits of Detection (LOD) and Quantitation (LOQ): The LOD is the lowest concentration of the analyte detected by the method. The LOQ is the minimum quantifiable concentration. The signal-to-noise ratio of 3:1 and 10:1 were taken as LOD and LOQ, respectively. In the present study the LOQ values of estriol were 12.5 and 10 ng/ml for GC-MS and HPLC, respectively. These values are also listed in Table 1.

Stability: Stability studies indicated that the samples were stable when kept at room temperature, +4°C and -20°C refrigeration temperature for 24 h (short-term) and 72 h (long-term). There was no significant change in the analysis over a period of 72 hours. The mean RSD between peak areas for the samples stored under refrigeration (± 1°C), at room temperature (25±1°C) and refrigeration (-20 ± 1°C) were found to be 5.241%, 5.42% and 6.43%, respectively, suggesting that the drug solution can be stored without any degradation over the studied time interval (Table 3).

Recovery: To determine the accuracy of the GC-MS and HPLC methods and to study the interference of formulation additives, the recovery
was checked as three different concentration levels (50, 150, 350 ng/ml) and analytical recovery experiments were performed by adding known amount of pure drugs to pre-analyzed samples of 50ng/ml commercial dosage form Gynoflor. The percent analytical recovery values were calculated by comparing concentration obtained from the spiked samples with actual added concentrations. These values are also listed in Table 4.

Comparison of the methods

Today, GC-MS and HPLC methods are important and widely used as analytical techniques of quantitative and qualitative analysis. As compared to HPLC, high-resolution capillary GC-MS has inherently high resolving power and high sensitivity with excellent precision and accuracy [12].

A survey of literature reveals that no GC-MS and HPLC methods for determination of estriol in pharmaceutical preparations. The present work describes the validation parameters stated either by USP 26 [13] or by the ICH guideline [14] to achieve GC-MS and HPLC methods for determination of estriol. The proposed methods are very effective for the assay of estriol in tablets (Figures 4 and 5).

The validity of the proposed methods was presented by recovery studies using the standard addition method. For this purpose, a known amount of reference drug was spiked to formulated tablets and the nominal value of drug was estimated by the proposed methods. Each level was repeated six times. The results were reproducible with low SD and RSD. No interference from the common excipients was observed. According to the statistical comparison (Student t-test) of the results there is no significant difference between GC-MS and HPLC methods (Table 5).
Conclusion

In this work, two new chromatographic methods have been developed and validated for routine determination of estriol hormone in pharmaceutical preparations. Linearity range, precision, accuracy, LOD and LOQ are suitable for the quantification of estriol in pharmaceutical preparations. The chromatographic run time of 7 min allows the analysis of a large number of samples in a short period of time. Therefore, the methods are also suitable for analysis of sample during accelerated stability studies, routine analysis of formulations and raw materials.

References

14. International Conference on Harmonisation (ICH) of Technical requirements for Registration of Pharmaceuticals for Human Use: Harmonised Tripartite Guideline on Validation of Analytical Procedures: Methodology, Recommended for Adoption at Step 4 of the ICH Process on November by the ICH Steering Committee, Published by IFPMA, Switzerland, 1996.